Potential Role of Psychedelics in the Treatment of Depressive Disorder

Depression remains a leading cause of global disability, with current treatments often offering limited benefit, especially in treatment-resistant cases. Psychedelics—psilocybin, lysergic acid diethylamide (LSD), ayahuasca, and 3,4-methylenedioxymethamphetamine (MDMA)—have re-emerged as potential therapies. Classic psychedelics act through 5-HT2A receptor agonism, enhancing neuroplasticity, elevating brain-derived neurotrophic factor (BDNF), and reducing default mode network activity, thereby alleviating rumination. Ayahuasca combines dimethyltryptamine (DMT) with monoamine oxidase inhibitors, while MDMA functions as a monoamine releaser and entactogen, increasing serotonin, norepinephrine, dopamine, and oxytocin to support emotional processing. Among these, psilocybin has the strongest clinical evidence, with randomized trials showing rapid and meaningful improvements in treatment-resistant and major depression, as well as cancer-related distress. Evidence for LSD and ayahuasca is emerging but more limited, while MDMA research has focused on posttraumatic stress disorder (PTSD) with consistent benefits for comorbid depression. Across compounds, adverse effects are generally mild and transient under supervision. Psychedelics represent a novel therapeutic approach that engages both neurobiological and psychological mechanisms, offering substantial potential to expand the treatment landscape for depressive disorders. However, their current use is limited by small sample sizes, short follow-up durations, difficulties in maintaining blinding, regulatory restrictions, and the need for controlled clinical settings to ensure safety. Larger, long-term trials are essential to confirm their efficacy, durability, and safety in broader populations.